82 results about "Mycobacterium fortuitum" patented technology

The invention relates to a CRISPR detection primer set for MTBC (Mycobacterium Tuberculosis Complex) and use thereof, and belongs to the technical field of gene detection. The primer set includes an amplification primer pair and a crRNA; the amplification primer pair is used to amplify a common conserved sequence of M. tuberculosis, M. bovis, M. africanum, M. canettii, and M. microti; the crRNA includes an anchor sequence and a guide sequence, wherein the anchor sequence is bound to a cas protein, and the guide sequence is matched with a targeted RNA fragment in the common conserved sequence.Through the primer set based on CRISPR detection technology, the detection of common conserved sequences of M. tuberculosis, M. bovis, M. africanum, M. canettii, and M. microti by CRISPR detection canquickly perform on-site detection of MTBC, and have the advantages of high specificity, high sensitivity and simplicity.

The invention discloses a primer and a probe for on-site rapid detection of mycobacterium tuberculosis complex and a kit thereof. The forward primer sequence is shown as SEQ ID No.1, the reverse primer sequence is shown as SEQ ID No.2, and the probe sequence is shown as SEQ ID No.3. The invention provides the PA-LFD primer and the probe for on-site distinctive, sensitive, simple and rapid detection of the mycobacterium tuberculosis complex (mycobacterium tuberculosis, mycobacterium bovis, African mycobacteria and Canna mycobacteria) and the kit containing the primer and the probe.

The present invention belongs to the field of gene engineering and diagnosis reagent technology, and aims at providing specific Rv3425 antigen for detecting tuberculosis and superior to available tuberculosis detecting reagent. The present invention provides specific Rv3425 antigen with high sensitivity in detecting pulmonary tuberculosis and other kinds of tuberculosis. The specific Rv3425 antigen as one immune dominant B-cell target antigen is used in preparing tuberculosis detecting reagent kit with high sensitivity, high safety and high reliability.

The invention discloses primers and a probe assembly for rapidly detecting mycobacterium paratuberculosis on site. A forward primer sequence is shown as SEQ ID No.1, a reverse primer sequence is shown as SEQ ID No.2, and a probe sequence is shown as SEQ ID No.3. The invention further discloses a kit for detecting the mycobacterium paratuberculosis. The primers, the probe assembly and the kit for detecting mycobacterium paratuberculosis RPA-nfo are high in sensitivity and strong in specificity, and mycobacterium paratuberculosis DNA of 8 copies/reaction can be detected at the minimum. The special instruments and equipment are not needed, by virtue of a thermostat water bath kettle or the temperature of the human armpit, the sensitive, specific and rapid detection for the mycobacterium paratuberculosis DNA can be carried out on the coarse lysate of a to-be-detected sample within 25min, and the primers, the probes and the kit are suitable for the on-site or primary-level diagnosis work of paratuberculosis.

The invention provides a method for preparing 9a-hydroxy androstendione, which comprises a step of performing fermentation culture on phytosterol by use of mycobacterium fortuitum ATCC 35855 so as to convert the phytosterol into 9a-hydroxy androstendione. The method is used for preparing 9a-hydroxy androstendione by use of mycobacterium fortuitum ATCC 35855 and corresponding fermentation liquid and fermentation technology; the cheap phytosterol can be adopted as a substrate; and moreover, the yield of the prepared 9a-hydroxy androstendione is high, a few byproducts are produced, the fermentation time is short, and a good way is provided for high-efficiency industrial production of 9a-hydroxy androstendione.

The invention relates to a diagnostic kit for identification of mycobacterium strains and detection of drug resistance and a preparation method thereof. The kit can quickly and accurately distinguish between the identification of mycobacterium strains and the detection of drug resistance in large quantities by using an oligonucleotide chip. Point mutations in the rpoB gene of Mycobacterium tuberculosis associated with drug resistance. The diagnostic kit for the identification of mycobacterium strains and the detection of drug resistance of the present invention contains an oligonucleotide chip, and the chip contains a complex composed of mycobacterium tuberculosis mycobacterium strain identification probes and drug resistance detection probes. Probe, mycobacterium tuberculosis rpoB gene, and fluorescent material, wherein the fluorescent material contains biotin-binding protein, which is used as the label of biotin and the corresponding probe to detect the hybridization of the sample amplification product.

The invention relates to a therapeutic vaccine for malignant tumors and a composition thereof. The therapeutic vaccine for malignant tumors is a tumor cell line which contains plasmid of antisense nucleic acid of human transforming growth factor beta (TGF-beta2); the therapeutic vaccine composition for malignant tumors comprises the therapeutic vaccine for malignant tumors and an immunopotentiator, and the immunopotentiator is one selected from the group consisting of a Corynebacterium parvum preparation, a non-cell Corynebacterium parvum preparation, a BCG polysaccharide, a nucleic acid preparation, a Nocardia rubra-cell wall skeleton preparation, a group A Streptococcus preparation, a non-cell group A Streptococcus preparation, a Pseudomonas aeruginosa preparation, a non-cell Pseudomonas aeruginosa preparation, a Brucella preparation, a non-cell Brucella preparation, a non-cell Mycobacterium vaccae preparation and a non-cell Mycobacterium smegmatis preparation, preferably the non-cell Corynebacterium parvum preparation; and the malignant tumors include a lung cancer, a liver cancer, a pancreatic cancer, leukemia, lymphoma, an ovarian cancer, a colon cancer, a stomach cancer and a breast cancer.

The invention belongs to the field of immunodetection and relates to a detection kit for distinguishing cow pathogenic mycobacteria infection from non-pathogenic mycobacteria infection and a method thereof. The detection reagent comprises combined fusion protein rE6-M63-H70 used as a specific stimulation origin, the combined fusion protein can effectively stimulate sensitized peripheral blood lymphocyte cultured in vitro to release Gamma-interferon (IFN-Gamma) at a high level. The cow IFN-Gamma release test established by using the detection reagent rE6-M63-H70 combined fusion protein as the stimulation origin overcomes the insufficiencies of serology detection method and the IFN-Gamma release test with PPD as the stimulation origin, thus enjoying very high sensitivity and specificity and distinguishing cow pathogenic mycobacteria ( such as mycobacterium bovis) infection from non-pathogenic mycobacteria (such as mycobacterium avium or non-pathogenic mycobacteria) infection and even distinguishing the cow pathogenic mycobacteria infection from BGG immunity; therefore, the detection kit and the method of the invention can be effectively used to detect the clinical cow pathogenic mycobacteria infection.

The invention relates to primers, probes and a method for liquid-phase chip detection of Mycobacterium tuberculosis drug-resistant gene mutation sites. The primers, probes and method are used for detecting drug-resistant gene mutation sites in Mycobacterium tuberculosis for drugs isoniazide, rifampicin and fonoquantel. The isoniazide drug-resistant mutation sites are positioned in katG gene and inhA gene; the rifampicin drug-resistant mutation sites are positioned in rpoB gene; and the fonoquantel drug-resistant mutation sites are positioned in gyrA gene. The method comprises the following steps: respectively carrying out homology analysis according to the nucleotide sequences of the four drug-resistance related genes in the gene bank, designing the primers and probes, carrying out PCR (polymerase chain reaction) twice, carrying out molecular hybridization, and carrying out detection by using a Luminex200 system, thereby determining whether the sample contains the drug-resistant mutation sites. The detection of drug-resistant gene mutation sites is of crucial importance for treating Mycobacterium tuberculosis infection by adopting correct therapeutic schedules. The primers, probes and method have the advantages of high detection speed, high sensitivity, high specificity and the like, are simple to operate, and are beneficial to popularization and application.

The invention relates to a method for extracting live bacteria RNA in Mycobacterium tuberculosis and a detection kit thereof, and particularly provides a method for extracting live bacteria RNA in Mycobacterium tuberculosis and a detection kit which is used for the live bacteria RNA in the Mycobacterium tuberculosis and is obtained by applying the method and combining fluorescent quantitative PCR technology. The kit can accurately, sensitively and quickly identify dead bacteria and the live bacteria of the Mycobacterium tuberculosis, reduce the cost and shorten the detection time, and more importantly, the kit is the basis of studies such as the diagnosis of tuberculosis, medicinal susceptibility experiments, the monitoring of chemotherapy response, the screening of new antitubercular medicaments, the prevention of the tuberculosis and the like.

The invention discloses a DNA marker for detecting the drug resistance of mycobacterium tuberculosis and application of the DNA marker. It is found that mutant protein Rv2783cD67N has the DNA polymerase activity without dependence on a DNA template, is not suppressed by POA and has the phosphorolysis singe-stranded DNA (SS DNS) activity; besides, the mutant protein Rv2783cD67N can not be combined with POA; by means of the locus mutation, the drug resistance of mycobacterium tuberculosis on PZA can be remarkably caused, the locus can serve as a mark locus for molecular diagnosis of PZA drug resistance of mycobacterium tuberculosis, and the detection rate and the precision of mycobacterium tuberculosis with PZA drug resistance can be easily improved. The diagnosis time of patients can be effectively shortened, and the treatment time and cost of patients can be saved. The DNA marker for detecting the drug resistance of mycobacterium tuberculosis and application of the DNA marker provide a new thought for finding new and more effective tuberculosis drug resistance molecular markers.

The invention discloses a preparation method and application of a series of novel pyridine derivatives. The derivatives can be used for the treatment of related diseases caused by mycobacterium species, especially for diseases caused by pathogenic mycobacterium, such as Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium avium and Mycobacterium marinum.

The invention discloses a deoxyribonucleic acid (DNA) aptamer for mycobacterium tuberculosis glycolipid antigen, which has a nucleotide sequence shown as SEQ ID No. 1. Experiments show that the DNA aptamer disclosed by the invention has high specificity and strong appetency when acting with the mycobacterium tuberculosis, and a novel preparation is provided for the diagnosis of tuberculosis. Meanwhile, experiments show that the DNA aptamer can inhibit the infection of the mycobacterium tuberculosis, and a novel path is provided for the treatment of the tuberculosis.

The invention discloses a method for producing A ring degradation products through plant sterol fermentation. The method comprises the following steps: (A) preparing a liquid inoculant containing mycobacterium fortuitum; (B) carrying out fermentation culture; (C) extracting and separating so as to obtain the A ring degradation products. The provided fermentation method for preparing A ring degradation products is carried out in an oil-free condition, thus the ring opening of A ring and B ring is effectively inhibited, thus the degradation is inhibited, the yield is increased, and the weight yield can reach 35 to 40%.

The invention provides a primer combination and an application thereof. The primer combination comprises a first primer group and a second primer group, wherein the nucleotide sequence of the first primer group is shown in the SEQ ID NO:1-2, and the nucleotide sequence of the second primer group is shown in the SEQ ID NO:3-4. The primer combination can specifically recognize the mycobacteria specific area-ITS area, has high homology between different mycobacteria, and is applicable to various mycobacteria and capable of being effectively used for recognizing the mycobacteria, particularly tuberculous mycobacteria and non-tuberculous mycobacteria.

The invention provides a drug target point based on mycobacterium tuberculosis ubiquitin ligase PafA and an application thereof, and belongs to the technical field of biomedicine. Specifically, the invention relates to a use of a 119-site serine of ubiquitin ligase PafA as a target point of an anti-tuberculosis drug. The serine site at the 119 site of the protein can specifically bind to a small molecule inhibitor 4-(2-aminoethyl)benzenesulfonylfluoride hydrochloride so that the activity of the mycobacterium tuberculosis ubiquitin ligase PafA is inhibited.

The invention discloses a probe and a kit for the common pathogens detection of skin infectious granuloma. The probe comprises a mycobacterium probe, a mycobacterium tuberculosis probe, a mycobacterium leprae probe, a mycobacterium avium probe, a mycobacterium intracellulare probe, a mycobacterium kansasii probe and a mycobacterium fortuitum probe, a candida albicans probe, a sporotrichum schenckii probe, a cladosporium trichoides probe, a Fonsecaea pedrosoi probe, and a Fonsecaea monophora probe; and a nocardia probe, an actinomycetes probe and a leishmania probe. The nucleotide sequence of each probe is shown in sequence tables SEQ ID NO.1-SEQ ID NO.15; and the kit comprises the probes and corresponding universal primers. According to the invention, through designing and optimizing the kit for carrying out pathogens screening and detection on common skin infectious granuloma, the improvement of the clinical diagnosis and the treatment efficiency is facilitated.

The invention discloses a method for identifying mycobacterium. The method comprises the following steps: acquiring a plurality of standard sequences of a plurality of mycobacteria so as to generate a mycobacterium sequence database; by comparing the standard sequences, obtaining a conservation section mutually owned by the standard sequences; preparing a PCR primer according to the conservation section; using the PCR primer to perform the PCR amplification of a DNA solution of the testing mycobacterium so as to obtain an amplification product of the testing mycobacterium; carrying out the sequencing reaction of the amplification product to obtain the sequencing product; carrying out the sequencing analysis of the sequencing product to obtain a sequence of the testing mycobacterium; and by comparing the testing sequence with the standard sequence in the mycobacterium sequence database, determining the type of the testing mycobacterium. The PCP primer is designed according to the conservation section of the standard sequences of various mycobacteria, only a pair of primers is needed for all PCRs and sequencing, thereby greatly reducing the quantity of oligonucleotide needed for experimental population.

The present invention discloses a PCR-RLB assay process of mycobacteria and the employed primers and probes. A pair of oligonucleotide primers and 35 species or type-specific probes are designed against the characteristics of DNA sequences of different types of mycobacterias. Via PCR-RLB assay process, 17 mycobacterias and Mycobacterium tuberculosis complexes, Mycobacterium Ulcerans/Marinum and 2 subspecies of Mycobacterium Kansasii can be identified for SGM. 14 species or subspecies can be identified for RGM. Compared with traditional identification process of mycobacteria, the present invention is a rapid, simple, practical, specific and sensitive assay method.

The invention belongs to the field of biomedicines, and relates to an application of vitamin C (ascorbic acid), as a single component, in preparation of medicines for treating and preventing tuberculosis. Through cytobiology and pharmacology experiments with combination of animal experiments, anti-tuberculosis pharmaceutical concentration of the vitamin C is determined; and on the basis of regulatory mechanism on oxidative stress status of mycobacterium tuberculosis after infection by macrophages, interference test is carried out, wherein a result proves that high-dose vitamin C can kill the mycobacterium tuberculosis, so that inhibition effect is achieved through NAC and catalase; the vitamin C treats the macrophages to generate H2O2, wherein functional effect is achieved with the signalchannel being same as H2O2; large-dose vitamin C kills mycobacteria, wherein inhibition function is achieved through a glutathione precursor NAC and CAT; high-dose vitamin C can infect the TNF-alpha signal pathway induced by RAW 264.7 cells via mediation of Bacillus Calmette-Guerin vaccine and H37Rv, thus achieving sterilization effect and influence on body immunity. The invention provides effective treatment strategy for clinical therapy and drug resistance of tuberculosis and tuberculosis in incubation period.

The invention discloses an application of deplazolid (LCB01-0371) in mycobacterium fortuitum infection. In the invention, a non-tuberculous mycobacteria resistant drug linezolid recommended by CLSI isused as a control, a microplate two-fold dilution method is used to measure the activity of the deplazolid against mycobacterium fortuitum, results show that the activity of the deplazolid on clinically isolated mycobacterium fortuitum is significantly better than that of the linezolid, mostly 2-4 times the antibacterial activity of the linezolid, so that a novel application of the deplazolid inthe treatment of diseases caused by the mycobacterium fortuitum infection is expected to be discovered.